Home » Stocks » KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. (KALV)

Stock Price: $10.74 USD -0.20 (-1.83%)
Updated Aug 4, 2020 1:46 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 191.68M
Revenue (ttm) 12.69M
Net Income (ttm) -29.12M
Shares Out 17.85M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $10.74
Previous Close $10.94
Change ($) -0.20
Change (%) -1.83%
Day's Open 10.93
Day's Range 10.28 - 10.93
Day's Volume 22,930
52-Week Range 5.61 - 18.96

More Stats

Market Cap 191.68M
Enterprise Value 125.02M
Earnings Date (est) Sep 14, 2020
Ex-Dividend Date n/a
Shares Outstanding 17.85M
Float 11.06M
EPS (basic) -1.64
EPS (diluted) -1.64
FCF / Share -2.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 391,842
Short Ratio 1.98
Short % of Float 3.43%
Beta 2.40
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 15.10
PB Ratio 2.09
Revenue 12.69M
Operating Income -40.53M
Net Income -29.12M
Free Cash Flow -45.04M
Net Cash 66.66M
Net Cash / Share 3.73
Gross Margin -216.74%
Operating Margin -319.41%
Profit Margin -229.40%
FCF Margin -354.89%
ROA -24.05%
ROE -32.26%
ROIC -38.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$27.00*
(151.40% upside)
Low
19.0
Current: $10.74
High
33.0
Target: 27.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year202020192018201720162015201420132012
Revenue12.6916.138.391.502.13-0.030.421.54
Revenue Growth-21.31%92.13%458.11%-29.49%---93.01%-73.02%-
Gross Profit12.6916.138.391.502.13-0.030.421.54
Operating Income-40.53-29.82-18.71-22.34-15.18-9.89-11.68-5.22-1.83
Net Income-29.12-20.82-15.81-18.60-11.44-7.23-13.36-5.68-2.05
Shares Outstanding17.7515.0810.324.650.590.260.040.030.03
Earnings Per Share-1.64-1.38-1.53-4.47-26.17-34.94-305.33-187.88-71.96
Operating Cash Flow-44.82-36.3710.56-23.72-13.16-6.37-11.25-4.86-1.84
Capital Expenditures-0.22-1.08-1.43-0.07-0.01-0.13-0.16-0.02-0.09
Free Cash Flow-45.04-37.459.13-23.80-13.17-6.49-11.41-4.88-1.93
Cash & Equivalents67.7110151.0630.9521.760.003.959.830.00
Total Debt1.06-0.28---6.573.06-
Net Cash / Debt66.6610150.7830.9521.760.00-2.626.770.00
Assets92.5311861.3934.3524.75-6.6410.11-
Liabilities8.7821.3934.143.0261.86-11.274.26-
Book Value83.7596.7427.2531.33-37.11--44.18-33.71-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name KalVista Pharmaceuticals, Inc.
Country United States
Employees 56
CEO T. Andrew Crockett

Stock Information

Ticker Symbol KALV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KALV

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.